Fresenius Kabi’s Biosimilar Stimufend® (pegfilgrastim-fpgk) is now available from Fresenius Kabi in the United States. Stimufend® was approved by the U.S. Food and Drug Administration (FDA) in September 2022 for use in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. It is Fresenius Kabi’s first U.S. biosimilar launch. The expansion of the company’s global biosimilars portfolio with a focus on oncology and immunology is an important milestone in its Vision 2026 growth strategy.
* Stimufend® (pegfilgrastim-fpgk) is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries. Stimufend is a pegfilgrastim biosimilar medicine of Neulasta®, which is a registered trademark of Amgen Inc.
Fresenius Kabi’s Biosimilar Stimufend® (pegfilgrastim-fpgk) is now available from Fresenius Kabi in the United States. Stimufend® was approved by the U.S. Food and Drug Administration (FDA) in September 2022 for use in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. It is Fresenius Kabi’s first U.S. biosimilar launch. The expansion of the company’s global biosimilars portfolio with a focus on oncology and immunology is an important milestone in its Vision 2026 growth strategy.
* Stimufend® (pegfilgrastim-fpgk) is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries. Stimufend is a pegfilgrastim biosimilar medicine of Neulasta®, which is a registered trademark of Amgen Inc.
February 28, 2023
London, UK
Morgan Stanley – European MedTech & Services Conference
March 23, 2023
Bad Homburg, Germany
Annual Report 2022
Consolidated Financial Statements and Management Report (IFRS)
The Fresenius Group expresses its deepest sympathies and condolences to the families and individuals affected by the earthquakes in Türkiye and Syria.
As first reaction after the catastrophic event, the company fully focused on connecting with its patients in the region. People dependent on our lifesaving products and services were transferred in case of destruction of local infrastructure. As further immediate step, Fresenius Medical Care established contact with its employees on site and intensively looks into options to support its local staff and their families.
Our disaster response teams are in full action and are being supported by units from other parts of the country. As global healthcare company, Fresenius is committed to support with urgently needed medical supply and works with humanitarian aid organizations to deliver donations of its most critical care products and services.
We remain fully committed to our patients, local staff, and partners on site.
Fresenius Kabi’s innovative Ivenix Infusion System is recognized by KLAS Research in a Performance Insights First Look article. This report shares very positive customer experiences from health care organizations currently using the Ivenix Infusion System in the U.S. Ivenix, acquired in 2022 by Fresenius Kabi, offers a technologically advanced infusion system, including a large-volume pump, infusion management, software tools, applications, and analytics to inform care, advance efficiency, reduce infusion-related errors, and drive down the total cost of ownership.
Fresenius Kabi’s innovative Ivenix Infusion System is recognized by KLAS Research in a Performance Insights First Look article. This report shares very positive customer experiences from health care organizations currently using the Ivenix Infusion System in the U.S. Ivenix, acquired in 2022 by Fresenius Kabi, offers a technologically advanced infusion system, including a large-volume pump, infusion management, software tools, applications, and analytics to inform care, advance efficiency, reduce infusion-related errors, and drive down the total cost of ownership.